摘要
沐舒坦（Ａｍｂｒｏｘｏｌ）是一种较新的粘液溶解剂，近年来其对呼吸系统的保护作用倍受关注，已有较多学者将其应用于ＡＲＤＳ的预防和治疗，取得了较好的临床效果，并对其机制进行了深入的研究。其预防和治疗ＡＲＤＳ的机制可能是：（１）减少ＴＮＦα和ＩＬ－１及相关炎性介质的释放，减轻ＳＩＲＳ在肺部的表现；（２）抗氧化作用，阻止氧自由基对肺组织的损伤；（３）刺激肺泡Ⅱ型上皮细胞合成、分泌内源性肺表面活性物质，同时抑制磷脂酶Ａ对肺表面活性物质的降解，增加肺的顺应性；（４）减轻ＡＲＤＳ时气管壁离子转运和电位差的破坏。临床应用大剂量沐舒坦对ＡＲＤＳ的预防、治疗和转归可能具有一定疗效。
Ambroxol is probably one of the most promising surfactant stimulating agents. It was paid much attention to its protective action in respiratory system in recent years, Ambroxol was applied in prophylaxis and treatment of ARDS and gained better clinical effect. The mechanism of prophylaxis and treatment of ARDS maybe: (1 ) decreasing release of pro-inflammatory(TNFα, IL-1 ) and correlative cytokines, relieving the manifestation of SIRS in lung; (2 ) enhancing of anti-oxidant defence mechanisms, preventing lung injury by reactive free oxygen radicals (e. g.. OH, HOCl); (3 ) stimulating synthesis and excretion of endogenetic pulmonary surfactant (PS) by lung alveolar type Ⅱ cells, preventing degradation of PS by phospholipase A, increasing compliance of lung; (4) relieving destruction potential difference of trachea wall in ARDS. There mayb have better clinical effect in prophylaxis and treatment of ARDS with Ambroxol.
出处
《创伤外科杂志》
2001年第2期145-147,共3页
Journal of Traumatic Surgery
关键词
沐舒坦
急性呼吸窘迫综合征
预防
治疗
acute respiratory distress syndrome(ARDS)
acute lung injury(ALI)
ambroxol
